drugset / Trial / NCT01414465

Orlistat Induced Modulation on the Fatty Acid Composition in Obese Females

NCT01414465

RandomizedParallel-groupDouble-blindTreatment

Summary

Orlistat is a popular drug approved for long-term use which produces weight loss by inhibiting triglycerides, main components of fats in the diet and reducing dietary fat absorption by up to 30%. The effect of this drug on human blood fatty acid profile has not been described yet. The FA composition of RBCs, plasma and platelets can be used to monitor of many pathological processes. This study presents alteration of FA composition in RBCM and phospholipids, triglycerides and cholesteryl esters from plasma of health obese female volunteers treated with nutritional orientation and orlistat (120 mg t.i.d) for 3 months.

Timeline

Start
2009-10
Primary completion
2010-03
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Orlistat Small molecule 120 mg

Indications